BridgeBio To Share Cardiovascular Outcomes Data In Patients With Variant And Wild-type ATTR-CM From ATTRibute-CM, Its Phase 3 Study Of Acoramidis In ATTR-CM

Benzinga14minutes ago

Catalyst Watch: CoreWeave IPO, Dollar Tree Earnings, Newsmax Pricing, and GameStop Crypto Intrigue

Seeking AlphaMar 21 15:00 ET

Alnylam Nabs Key Additional Indication for Amvuttra

Seeking AlphaMar 20 18:13 ET

The Analyst Verdict: Blueprint Medicines In The Eyes Of 14 Experts

BenzingaMar 20 16:00 ET

Morgan Stanley Assumes Blueprint Medicines at Equal-Weight, Lowers Price Target of $100

BenzingaMar 20 11:04 ET · Ratings

Blueprint Medicines Analyst Ratings

BenzingaMar 20 11:02 ET · Ratings